JPMorgan Chase & Co. Analysts Give Merck KGaA (FRA:MRK) a €104.00 Price Target

Share on StockTwits

JPMorgan Chase & Co. set a €104.00 ($120.93) price objective on Merck KGaA (FRA:MRK) in a report published on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other brokerages also recently commented on MRK. Deutsche Bank set a €104.00 ($120.93) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Monday, November 18th. Goldman Sachs Group set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the company a sell rating in a research report on Tuesday, December 3rd. HSBC set a €96.00 ($111.63) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Wednesday, November 27th. Sanford C. Bernstein set a €114.00 ($132.56) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Thursday, November 14th. Finally, Nord/LB set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the company a neutral rating in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of €103.07 ($119.84).

FRA:MRK opened at €104.35 ($121.34) on Friday. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72). The business has a 50 day moving average price of €106.82 and a 200-day moving average price of €98.03.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: What is a death cross?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hartford Financial Services Group Inc  Shares Sold by Benin Management CORP
Hartford Financial Services Group Inc Shares Sold by Benin Management CORP
SYSCO Co.  Position Reduced by Benin Management CORP
SYSCO Co. Position Reduced by Benin Management CORP
Benin Management CORP Purchases 1,000 Shares of Merck & Co., Inc.
Benin Management CORP Purchases 1,000 Shares of Merck & Co., Inc.
11,677 Shares in Truist Financial Corporation  Acquired by Benin Management CORP
11,677 Shares in Truist Financial Corporation Acquired by Benin Management CORP
Benin Management CORP Decreases Stock Holdings in Paychex, Inc.
Benin Management CORP Decreases Stock Holdings in Paychex, Inc.
Benin Management CORP Decreases Stock Position in Halliburton
Benin Management CORP Decreases Stock Position in Halliburton


© 2006-2020 Ticker Report